150 related articles for article (PubMed ID: 19523342)
1. Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas.
Cho DY; Lin SZ; Yang WK; Hsu DM; Lee HC; Lee WY; Liu SP
Cell Transplant; 2009; 18(9):977-83. PubMed ID: 19523342
[TBL] [Abstract][Full Text] [Related]
2. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
3. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
5. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique.
Imura K; Ueda Y; Hayashi T; Itoh T; Shimizu K; Tamai H; Yano Y; Naito K; Kohara J; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H
Int J Oncol; 2006 Sep; 29(3):531-9. PubMed ID: 16865268
[TBL] [Abstract][Full Text] [Related]
6. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic effects of treatment of pancreatic carcinoma by interleukin-23 and apoptotic cell antigen-modified dendritic cell vaccine: experiment with mice].
Tan G; Wang ZY; Yin S
Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(14):943-6. PubMed ID: 16759530
[TBL] [Abstract][Full Text] [Related]
8. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
Schlienger K; Chu CS; Woo EY; Rivers PM; Toll AJ; Hudson B; Maus MV; Riley JL; Choi Y; Coukos G; Kaiser LR; Rubin SC; Levine BL; Carroll RG; June CH
Clin Cancer Res; 2003 Apr; 9(4):1517-27. PubMed ID: 12684428
[TBL] [Abstract][Full Text] [Related]
9. Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Iida T; Yamaue H
Int J Oncol; 2008 Feb; 32(2):459-66. PubMed ID: 18202769
[TBL] [Abstract][Full Text] [Related]
10. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
11. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.
Bohnenkamp HR; Coleman J; Burchell JM; Taylor-Papadimitriou J; Noll T
Cell Immunol; 2004; 231(1-2):112-25. PubMed ID: 15919376
[TBL] [Abstract][Full Text] [Related]
12. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells.
Liu Y; Chiriva-Internati M; You C; Luo R; You H; Prasad CK; Grizzi F; Cobos E; Klimberg VS; Kay H; Mehta JL; Hermonat PL
Cancer Gene Ther; 2005 Mar; 12(3):304-12. PubMed ID: 15565181
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.
Suzuki T; Fukuhara T; Tanaka M; Nakamura A; Akiyama K; Sakakibara T; Koinuma D; Kikuchi T; Tazawa R; Maemondo M; Hagiwara K; Saijo Y; Nukiwa T
Clin Cancer Res; 2005 Jan; 11(1):58-66. PubMed ID: 15671528
[TBL] [Abstract][Full Text] [Related]
14. Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes.
Tanaka F; Yamaguchi H; Haraguchi N; Mashino K; Ohta M; Inoue H; Mori M
Int J Oncol; 2006 Nov; 29(5):1263-8. PubMed ID: 17016660
[TBL] [Abstract][Full Text] [Related]
15. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
[TBL] [Abstract][Full Text] [Related]
16. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
Bodey B; Bodey B; Kaiser HE
In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
[TBL] [Abstract][Full Text] [Related]
17. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
18. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy.
Feili-Hariri M; Falkner DH; Morel PA
J Leukoc Biol; 2005 Sep; 78(3):656-64. PubMed ID: 15961574
[TBL] [Abstract][Full Text] [Related]
19. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A
Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925
[TBL] [Abstract][Full Text] [Related]
20. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]